SYNDAX PHARMACEUTICALS INC (SNDX)

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024

SNDX stock results show that Syndax Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

First Week of June 21st Options Trading For Syndax Pharmaceuticals (SNDX)

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

/PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Noteworthy Wednesday Option Activity: SNDX, BYON, CNXC

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Noteworthy Tuesday Option Activity: EHC, CLF, SNDX

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Noteworthy Friday Option Activity: DPZ, IMXI, SNDX

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Pharmaceuticals files for a mixed securities shelf (NASDAQ:SNDX)

Syndax Pharmaceuticals files prospectus for mixed shelf offering but it's not an offer to sell securities.

FDA accepts Incyte application for graft-versus-host disease drug (NASDAQ:INCY)

The FDA has accepted Incyte’s (INCY) market application for priority review of its drug candidate axatilimab for the treatment of chronic graft-versus-host disease. Read more here.

Syndax Pharmaceuticals GAAP EPS of -$1.00 misses by $0.04 (NASDAQ:SNDX)

Read about Syndax Pharmaceuticals' Q4 financial results, which missed expectations by $0.04.

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

– BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024 – – NDA for revumenib in R/R KMT2Ar acute...

Syndax Announces Participation at Two Upcoming Investor Conferences

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Investors growing more bullish on SMID cap biotech stocks (NASDAQ:ALNY)

Investors are more bullish about small and mid-cap biotech stocks this year, with Merus (MRUS) and Fusion (FUSN) viewed as most likely to outperform, according to TD Cowen.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Announces Participation at Two Upcoming Investor Conferences

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Notable Thursday Option Activity: GNRC, SNDX, LW

Barron’s cites cancer and weight loss plays for biotech M&A (NASDAQ:VKTX)

On the back of recent deals involving big pharma, Barron’s issued positive remarks on a possible acceleration of biotech M&A activity on Tuesday. Read more here.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Syndax highlights recent updates and anticipated 2024 milestones (NASDAQ:SNDX)

Syndax Pharmaceuticals submits new drug application for revumenib, plans to complete enrollment in pivotal trial and extend runway through 2026.

Syndax Highlights Recent Updates and Anticipated 2024 Milestones

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

Mizuho starts Syndax at buy; cites market potential, cash position (NASDAQ:SNDX)

Mizuho has initiated coverage of Syndax Pharmaceuticals (SNDX) with a buy rating citing the near-term commercial opportunities for its drug candidates revumenib

Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an...

Syndax down 4%, prices $200M equity offering (NASDAQ:SNDX)

Syndax Pharmaceuticals prices $200M public offering, offering ~10.8M shares at $18.50 each.

Syndax Announces Pricing of $200 Million Public Offering of Common Stock

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative...